Javid Niloofar, Asadipour Ali, Salarkia Ehsan, Langarizadeh Mohammad Amin, Sharifi Fatemeh, Mahdavi Mohammad, Amirheidari Bagher, Iraji Aida, Rezaiezadeh Hojjat, Hassanpour Gholamreza, Pourshojaei Yaghoub
Department of Medicinal Chemistry, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.
Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Sci Rep. 2025 Jan 20;15(1):2571. doi: 10.1038/s41598-025-86035-6.
Leishmaniasis is a parasitic disease caused by protozoan organisms belonging to the Leishmania genus, affecting many individuals worldwide, with the burden surpassing one million cases. This disease leads to considerable morbidity and mortality, predominantly within tropical and subtropical regions. The current therapeutic options for leishmaniasis are far from ideal, as they fail to achieve a level of efficacy that can be deemed universally effective. The primary drawbacks of existing treatments include severe side effects, substantial toxicity, high financial costs, extended treatment regimens, and the discomfort associated with injectable forms of administration. Additionally, the growing issue of drug resistance presents a formidable challenge, further complicating disease management and control efforts. In light of these limitations, developing new therapeutic agents that can effectively disrupt the parasite's life cycle at multiple stages is of paramount importance. This study endeavors to address this critical need by focusing on the design and synthesis of a series of novel compounds. Fifteen derivatives incorporating the nitrochromene pharmacophore were meticulously synthesized using the Henry reaction. After synthesizing these derivatives, a comprehensive evaluation of their biological activity against L. tropica was undertaken. This assessment employed both in vitro techniques to directly observe the compounds' effects on the parasite and in silico methods, specifically molecular docking studies, to predict and analyze the interaction between the synthesized compounds and various target proteins of the parasite. The dual approach of combining experimental and computational methods aims to provide a robust understanding of the compounds' mechanisms of action and their potential as effective anti-leishmanial agents. This integrative strategy not only enhances the reliability of the findings but also offers valuable insights that could guide future drug development efforts in combating leishmaniasis.
利什曼病是一种由属于利什曼原虫属的原生动物引起的寄生虫病,影响着全球许多人,病例负担超过100万例。这种疾病导致相当高的发病率和死亡率,主要发生在热带和亚热带地区。目前利什曼病的治疗选择远非理想,因为它们未能达到普遍有效的疗效水平。现有治疗方法的主要缺点包括严重的副作用、高毒性、高经济成本、延长的治疗方案以及与注射给药形式相关的不适。此外,耐药性问题日益严重,这是一个巨大的挑战,使疾病管理和控制工作更加复杂。鉴于这些局限性,开发能够在多个阶段有效破坏寄生虫生命周期的新型治疗药物至关重要。本研究致力于通过专注于一系列新型化合物的设计和合成来满足这一关键需求。使用亨利反应精心合成了15种含有硝基色烯药效团的衍生物。合成这些衍生物后,对它们针对热带利什曼原虫的生物活性进行了全面评估。该评估采用了体外技术直接观察化合物对寄生虫的影响以及计算机模拟方法,特别是分子对接研究来预测和分析合成化合物与寄生虫各种靶蛋白之间的相互作用。将实验方法和计算方法相结合的双重方法旨在深入了解化合物的作用机制及其作为有效抗利什曼病药物的潜力。这种综合策略不仅提高了研究结果的可靠性,还提供了有价值的见解,可指导未来抗利什曼病药物开发工作。